FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:17-26 July 3, 2003 Number 1 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Elfenbein, G. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The prognosis for women with primary breast cancer and 10 or more involved axillary lymph nodes is poor. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse.

Methods We randomly assigned 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation.

Results Among the 511 eligible patients, there was no significant difference in disease-free survival, overall survival, or the time to recurrence between those who received CAF alone and those who received CAF plus high-dose chemotherapy and stem-cell transplantation. Among 417 patients fulfilling strict eligibility criteria, the time to recurrence was longer for patients who underwent stem-cell transplantation than for those who received CAF alone. In the transplantation group, nine patients died of transplantation-related complications and a myelodysplastic syndrome or acute myeloid leukemia developed in nine.

Conclusions The addition of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation to six cycles of adjuvant chemotherapy with CAF may reduce the risk of relapse but does not improve the outcome among patients with primary breast cancer and at least 10 involved axillary lymph nodes. Conventional-dose adjuvant chemotherapy remains the standard of care for such patients.

Source Information

From the Division of Hematology–Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago (M.S.T., W.JG.); Dana–Farber Cancer Institute, Boston (R.G.); Inova Fairfax Hospital, Falls Church, Va. (N.J.R.); Texas Transplant Institute, San Antonio (C.F.L.); Breast Center, Baylor College of Medicine and Methodist Hospital, Houston (C.K.O.); University of Alabama at Birmingham, Birmingham (W.P.V.); the Division of Radiation Oncology, Mayo Clinic, Rochester, Minn. (T.M.P.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.F.); Our Lady of Mercy Cancer Center, New York Medical College, Bronx (E.P.); and Case Western Reserve University School of Medicine, Ireland Cancer Center, Cleveland (H.M.L.).

Drs. Robert and Lazarus contributed equally to the article.

Address reprint requests to Dr. Tallman at the Division of Hematology–Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair St., Suite 850, Chicago, IL 60611, or at m-tallman{at}northwestern.edu.

Full Text of this Article

Related Letters:

High-Dose Chemotherapy for Breast Cancer
Wheatley K., Gray R. G., Ives N. J., Tartarone A., Iodice G., Di Renzo N., Mangano M. M., Dazzi C., Cariello A., Rodenhuis S., van Tinteren H., de Vries E. G.E., Tallman M. S., Robert N. J., Lazarus H. M., Elfenbein G. J.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:1476-1479, Oct 9, 2003. Correspondence

This article has been cited by other articles:

• Colleoni, M., Sun, Z., Martinelli, G., Basser, R. L., Coates, A. S., Gelber, R. D., Green, M. D., Peccatori, F., Cinieri, S., Aebi, S., Viale, G., Price, K. N., Goldhirsch, A., for the International Breast Cancer Study Group, (2009). The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 20: 1344-1351 [Abstract] [Full Text]  
• DeMichele, A., Gray, R., Horn, M., Chen, J., Aplenc, R., Vaughan, W. P., Tallman, M. S. (2009). Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer. Cancer Res. 69: 4184-4191 [Abstract] [Full Text]  
• Zander, A. R., Schmoor, C., Kroger, N., Kruger, W., Mobus, V., Frickhofen, N., Metzner, B., Berdel, W. E., Koenigsmann, M., Thiel, E., Wandt, H., Possinger, K., Kreienberg, R., Schumacher, M., Jonat, W. (2008). Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Ann Oncol 19: 1082-1089 [Abstract] [Full Text]  
• Lazarus, H. M., Phillips, G. L., Herzig, R. H., Hurd, D. D., Wolff, S. N., Herzig, G. P. (2008). High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later. JCO 26: 2240-2243 [Full Text]  
• Gluz, O., Nitz, U. A., Harbeck, N., Ting, E., Kates, R., Herr, A., Lindemann, W., Jackisch, C., Berdel, W. E., Kirchner, H., Metzner, B., Werner, F., Schutt, G., Frick, M., Poremba, C., Diallo-Danebrock, R., Mohrmann, S., On behalf of the West German Study Group, (2008). Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 19: 861-870 [Abstract] [Full Text]  
• Tran, L.-P. P., Grabinski, J. L. (2008). Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux. Journal of Pharmacy Practice 21: 46-56 [Abstract]  
• Kobayashi, A., Hara, H., Ohashi, M., Nishimoto, T., Yoshida, K., Ohkohchi, N., Yoshida, T., Aoki, K. (2007). Allogeneic MHC Gene Transfer Enhances an Effective Antitumor Immunity in the Early Period of Autologous Hematopoietic Stem Cell Transplantation. Clin. Cancer Res. 13: 7469-7479 [Abstract] [Full Text]  
• Nieto, Y., Nawaz, F., Jones, R. B., Shpall, E. J., Nawaz, S. (2007). Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast Cancer. JCO 25: 4405-4413 [Abstract] [Full Text]  
• Moore, H. C.F., Green, S. J., Gralow, J. R., Bearman, S. I., Lew, D., Barlow, W. E., Hudis, C., Wolff, A. C., Ingle, J. N., Chew, H. K., Elias, A. D., Livingston, R. B., Martino, S. (2007). Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623. JCO 25: 1677-1682 [Abstract] [Full Text]  
• Wilking, N, Lidbrink, E, Wiklund, T, Erikstein, B, Lindman, H, Malmstrom, P, Kellokumpu-Lehtinen, P, Bengtsson, N-O, Soderlund, G, Anker, G, Wist, E, Ottosson, S, Salminen, E, Ljungman, P, Holte, H, Nilsson, J, Blomqvist, C, Bergh, J, On behalf of the Scandinavian Breast Group, study, (2007). Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 18: 694-700 [Abstract] [Full Text]  
• Bertuzzi, A., Gullo, G., Rimassa, L., Castagna, L., Santoro, A. (2006). High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients. Ann Oncol 17: 719-720 [Full Text]  
• Rodenhuis, S., Bontenbal, M., van Hoesel, Q. G. C. M., Smit, W. M., Nooij, M. A., Voest, E. E., van der Wall, E., Hupperets, P., van Tinteren, H., Peterse, J. L., van de Vijver, M. J., de Vries, E. G. E., for the Netherlands Working Party on Autologous Tr, (2006). Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17: 588-596 [Abstract] [Full Text]  
• International Breast Cancer Study Group, (2006). Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95. JCO 24: 370-378 [Abstract] [Full Text]  
• Kroger, N., Milde-Langosch, K., Riethdorf, S., Schmoor, C., Schumacher, M., Zander, A. R., Loning, T. (2006). Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients. Clin. Cancer Res. 12: 159-168 [Abstract] [Full Text]  
• Nieboer, P., Buijs, C., Rodenhuis, S., Seynaeve, C., Beex, L. V.A.M., van der Wall, E., Richel, D. J., Nooij, M. A., Voest, E. E., Hupperets, P., Mulder, N. H., van der Graaf, W. T.A., TenVergert, E. M., van Tinteren, H., de Vries, E. G.E. (2005). Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study. JCO 23: 8296-8304 [Abstract] [Full Text]  
• Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., Lenihan, D. J. (2005). Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment. JCO 23: 7820-7826 [Abstract] [Full Text]  
• Cianfrocca, M., Gradishar, W. J. (2005). Controversies in the Therapy of Early Stage Breast Cancer. The Oncologist 10: 766-779 [Abstract] [Full Text]  
• Stewart, D. A., Paterson, A. H. G., Ruether, J. D., Russell, J., Craighead, P., Smylie, M., Mackey, J. (2005). High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study. Ann Oncol 16: 1463-1468 [Abstract] [Full Text]  
• DeMichele, A., Aplenc, R., Botbyl, J., Colligan, T., Wray, L., Klein-Cabral, M., Foulkes, A., Gimotty, P., Glick, J., Weber, B., Stadtmauer, E., Rebbeck, T. R. (2005). Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort. JCO 23: 5552-5559 [Abstract] [Full Text]  
• Peters, W. P., Rosner, G. L., Vredenburgh, J. J., Shpall, E. J., Crump, M., Richardson, P. G., Schuster, M. W., Marks, L. B., Cirrincione, C., Norton, L., Henderson, I.C., Schilsky, R. L., Hurd, D. D. (2005). Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13. JCO 23: 2191-2200 [Abstract] [Full Text]  
• Wieand, S., Murphy, K. (2004). A Commentary on Treatment at Random: The Ultimate Science or the Betrayal of Hippocrates?. JCO 22: 5009-5011 [Full Text]  
• Schneeweiss, A., Diel, I., Hensel, M., Kaul, S., Sinn, H.-P., Unnebrink, K., Rudlowski, C., Lauschner, I., Schuetz, F., Egerer, G., Haas, R., Ho, A. D., Bastert, G. (2004). Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy. Ann Oncol 15: 1627-1632 [Abstract] [Full Text]  
• Nieto, Y., Vredenburgh, J. J., Shpall, E. J., Bearman, S. I., McSweeney, P. A., Chao, N., Rizzieri, D., Gasparetto, C., Matthes, S., Baron, A. E., Jones, R. B. (2004). Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer. Clin. Cancer Res. 10: 7136-7143 [Abstract] [Full Text]  
• Leonard, R. C. F., Lind, M., Twelves, C., Coleman, R., van Belle, S., Wilson, C., Ledermann, J., Kennedy, I., Barrett-Lee, P., Perren, T., Verrill, M., Cameron, D., Foster, E., Yellowlees, A., Crown, J. (2004). Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial. JNCI J Natl Cancer Inst 96: 1076-1083 [Abstract] [Full Text]  
• Zander, A.R., Kroger, N., Schmoor, C., Kruger, W., Mobus, V., Frickhofen, N., Metzner, B., Schultze, W., Berdel, W.E., Koenigsmann, M., Thiel, E., Wandt, H., Possinger, K., Trumper, L., Kreienberg, R., Carstensen, M., Schmidt, E.H., Janicke, F., Schumacher, M., Jonat, W. (2004). High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial. JCO 22: 2273-2283 [Abstract] [Full Text]  
• Hortobagyi, G. N. (2004). What Is the Role of High-Dose Chemotherapy in the Era of Targeted Therapies?. JCO 22: 2263-2266 [Full Text]  
• Somlo, G., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R. Jr, Shibata, S., Chu, P., Forman, S., Lim, D., Twardowski, P., Weitzel, J., Alvarnas, J., Kogut, N., Schriber, J., Fermin, E., Yen, Y., Damon, L., Doroshow, J. H. (2004). Prognostic Indicators and Survival in Patients With Stage IIIB Inflammatory Breast Carcinoma After Dose-Intense Chemotherapy. JCO 22: 1839-1848 [Abstract] [Full Text]  
• Nieto, Y., Nawaz, S., Shpall, E. J., Bearman, S. I., Murphy, J., Jones, R. B. (2004). Long-Term Analysis and Prospective Validation of a Prognostic Model for Patients with High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy. Clin. Cancer Res. 10: 2609-2617 [Abstract] [Full Text]  
• Gratwohl, A., Baldomero, H., Demirer, T., Rosti, G., Dini, G., Ladenstein, R., Urbano-Ispizua, A. (2004). Hematopoetic stem cell transplantation for solid tumors in Europe. Ann Oncol 15: 653-660 [Abstract] [Full Text]  
• Wheatley, K., Gray, R. G., Ives, N. J., Tartarone, A., Iodice, G., Di Renzo, N., Mangano, M. M., Dazzi, C., Cariello, A., Rodenhuis, S., van Tinteren, H., de Vries, E. G.E., Tallman, M. S., Robert, N. J., Lazarus, H. M., Elfenbein, G. J. (2003). High-Dose Chemotherapy for Breast Cancer. NEJM 349: 1476-1479 [Full Text]  
• (2003). High-Dose Chemo with Stem-Cell Rescue for High-Risk Breast Cancer?. JWatch Women's Health 2003: 4-4 [Full Text]  
• (2003). High-Dose Chemotherapy Plus Stem-Cell Rescue in High-Risk Breast Cancer. JWatch General 2003: 1-1 [Full Text]  
• Rodenhuis, S., Bontenbal, M., Beex, L. V.A.M., Wagstaff, J., Richel, D. J., Nooij, M. A., Voest, E. E., Hupperets, P., van Tinteren, H., Peterse, H. L., TenVergert, E. M., de Vries, E. G.E., the Netherlands Working Party on Autologous Transp, (2003). High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer. NEJM 349: 7-16 [Abstract] [Full Text]  
• Elfenbein, G. J. (2003). Stem-Cell Transplantation for High-Risk Breast Cancer. NEJM 349: 80-82 [Full Text]